Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Recruiting × Pleural Effusion, Malignant × sugemalimab × Clear all

Phase

Phase EARLY_PHASE1 1

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Carcinoma, Non-Small-Cell Lung 2 Small Cell Lung Carcinoma 1 Pleural Effusion, Malignant 1 Neoplasm, Residual 1 NSCLC 1 Lung Neoplasms 1

Interventions

aldesleukin 2 Pharmaceutical Preparations 2 Interleukin-2 2 tocilizumab 1 sugemalimab 1 Thoracoscopy 1 Immunotherapy, Adoptive 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06097962 2026-03-20

Safety and Efficacy of NK510 to Treat NSCLC

Base Therapeutics (Shanghai) Co., Ltd.

Phase EARLY_PHASE1 Recruiting

Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon ⚡